Non Metastatic Melanoma Recurrence Risk

Castle Biosciences Announced Data Was Strong Predictor for Classifying
Aug 6, 2013
Castle Biosciences has announced that data from studies of its DecisionDx-Melanoma test confirm previous studies, indicating that the gene expression profile test is a strong predictor for classifying which Stage I or II non-metastatic ...

Tags: Non-Metastatic Melanoma Recurrence Risk